352 material Form 8-K filings that 310 companies we cover made with the SEC in August 2024, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
ResMed expanded its board of directors to 11 and appointed Christopher DelOrefice, executive vice president and chief financial officer of Becton, Dickinson and Company, as a director on August 15, 2024. He will also serve on the board's audit committee and stand for re-election at the annual meeting on November 21, 2024. The filing reports no financial results or guidance changes tied to this appointment.
Board expanded from its prior size to 11 directors; DelOrefice appointed August 15, 2024 at a regularly scheduled board meeting
DelOrefice has been CFO of Becton, Dickinson and Company since September 2021 and previously held roles at Johnson & Johnson
Appointed to the audit committee; term runs to the 2024 annual meeting on November 21, 2024
He will receive director compensation on a pro rata basis and a standard indemnification agreement with ResMed
Directors Jeffrey Margolis and Thomas Carella resigned from the board effective immediately, with the company saying the resignations were not due to any disagreement. Mr. Margolis also entered a consulting agreement with the company's primary operating subsidiary, and the board cut its authorized size and reshuffled committee leadership to keep Nasdaq listing compliance.
Jeffrey Margolis and Thomas Carella resigned from the board, notified August 13, 2024 and August 14, 2024, respectively
Board authorized size reduced from eleven to nine directors; Margaret McCarthy reclassified from Class I to Class III
Margolis consulting agreement effective August 13, 2024, with a one-time payment of $18,333 and monthly retainers ranging from $9,167 to $21,667 through June 2026
Fresh Del Monte Produce Inc. disclosed that Jesus Rodriguez Calvo, its Senior Vice President of North American Sales, will retire from the company effective August 16, 2024. The company and its Board thanked him for his service. The filing does not name a successor or give further details about the departure.
Jesus Rodriguez Calvo, Senior Vice President, North American Sales, retires effective August 16, 2024.
The company and Board of Directors thanked Mr. Calvo for his service.
The filing does not name a successor or describe any compensation arrangements.
The report was signed by Chief Financial Officer Monica Vicente on August 16, 2024.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.